TD SYNNEX (US:SNX) Benzinga·2025-03-27 16:12Market Overview - U.S. stocks traded lower, with the Dow Jones index falling approximately 90 points, down 0.23% to 42,358.68, NASDAQ down 0.05% to 17,890.40, and S&P 500 down 0.04% to 5,709.99 [1] - Consumer discretionary shares increased by 1.2%, while information technology shares decreased by 0.3% [1] Company Performance - TD SYNNEX Corp's shares dropped around 18% after reporting first-quarter revenue of $14.53 billion, which was a 4.0% year-over-year increase but missed analyst expectations of $14.79 billion. The adjusted EPS was $2.80, below the expected $2.91 [2] Commodity Market - Oil prices increased by 0.1% to $69.68, gold rose by 1.3% to $3,062.40, silver went up by 1% to $34.555, while copper fell by 2.6% to $5.1035 [5] European Market - European shares declined, with the eurozone's STOXX 600 down 0.57%, Germany's DAX 40 down 0.87%, and France's CAC 40 down 0.42% [6] Asian Market - Asian markets closed mostly higher, with Japan's Nikkei 225 down 0.60%, while China's Shanghai Composite Index, Hong Kong's Hang Seng Index, and India's BSE Sensex all saw gains of 0.15%, 0.41%, and 0.41% respectively [7] Notable Stock Movements - Soleno Therapeutics, Inc. shares surged 41% to $69.22 after FDA approval for its first commercial drug [9] - Greenland Technologies Holding Corporation shares increased by 62% to $2.09 following a year-over-year EPS increase [9] - Dermata Therapeutics, Inc. shares rose 26% to $1.6996 after positive Phase 3 trial results [9] - Nxu, Inc. shares fell 38% to $0.1641 due to a 1-for-20 reverse stock split [9] - Equillium, Inc. shares dropped 34% to $0.4878 after disappointing Phase 3 study results [9] - Auddia Inc. shares decreased by 30% to $0.2345 following a 1-for-17 reverse stock split [9]